Cargando…

New strategies for neuro protection in glaucoma

Glaucoma is a progressive, irreversible loss of retinal ganglion cells (RGCs) and axons that results in characteristic optic atrophy and corresponding progressive visual field defect. The exact mechanisms underlying glaucomatous neuron loss are not clear. The main risk factor for glaucoma onset and...

Descripción completa

Detalles Bibliográficos
Autores principales: Xuejiao, Yang, Junwei, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520966/
https://www.ncbi.nlm.nih.gov/pubmed/36187483
http://dx.doi.org/10.3389/fcell.2022.983195
_version_ 1784799742276927488
author Xuejiao, Yang
Junwei, Yan
author_facet Xuejiao, Yang
Junwei, Yan
author_sort Xuejiao, Yang
collection PubMed
description Glaucoma is a progressive, irreversible loss of retinal ganglion cells (RGCs) and axons that results in characteristic optic atrophy and corresponding progressive visual field defect. The exact mechanisms underlying glaucomatous neuron loss are not clear. The main risk factor for glaucoma onset and development is high intraocular pressure (IOP), however traditional IOP-lowering therapies are often not sufficient to prevent degeneration of RGCs and the vision loss may progress, indicating the need for complementary neuroprotective therapy. This review summarizes the progress for neuro protection in glaucoma in recent 5 years, including modulation of neuroinflammation, gene and cell therapy, dietary supplementation, and sustained-release system.
format Online
Article
Text
id pubmed-9520966
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95209662022-09-30 New strategies for neuro protection in glaucoma Xuejiao, Yang Junwei, Yan Front Cell Dev Biol Cell and Developmental Biology Glaucoma is a progressive, irreversible loss of retinal ganglion cells (RGCs) and axons that results in characteristic optic atrophy and corresponding progressive visual field defect. The exact mechanisms underlying glaucomatous neuron loss are not clear. The main risk factor for glaucoma onset and development is high intraocular pressure (IOP), however traditional IOP-lowering therapies are often not sufficient to prevent degeneration of RGCs and the vision loss may progress, indicating the need for complementary neuroprotective therapy. This review summarizes the progress for neuro protection in glaucoma in recent 5 years, including modulation of neuroinflammation, gene and cell therapy, dietary supplementation, and sustained-release system. Frontiers Media S.A. 2022-09-15 /pmc/articles/PMC9520966/ /pubmed/36187483 http://dx.doi.org/10.3389/fcell.2022.983195 Text en Copyright © 2022 Xuejiao and Junwei. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Xuejiao, Yang
Junwei, Yan
New strategies for neuro protection in glaucoma
title New strategies for neuro protection in glaucoma
title_full New strategies for neuro protection in glaucoma
title_fullStr New strategies for neuro protection in glaucoma
title_full_unstemmed New strategies for neuro protection in glaucoma
title_short New strategies for neuro protection in glaucoma
title_sort new strategies for neuro protection in glaucoma
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520966/
https://www.ncbi.nlm.nih.gov/pubmed/36187483
http://dx.doi.org/10.3389/fcell.2022.983195
work_keys_str_mv AT xuejiaoyang newstrategiesforneuroprotectioninglaucoma
AT junweiyan newstrategiesforneuroprotectioninglaucoma